Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin

Eur Respir J. 2020 May 7;55(5):1901903. doi: 10.1183/13993003.01903-2019. Print 2020 May.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Antitubercular Agents / blood
  • Antitubercular Agents / pharmacokinetics
  • Drug Monitoring / methods*
  • Female
  • Humans
  • Linezolid / blood*
  • Linezolid / pharmacokinetics
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Moxifloxacin / blood*
  • Moxifloxacin / pharmacokinetics
  • Netherlands
  • Prospective Studies
  • Saliva / metabolism*
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents
  • Linezolid
  • Moxifloxacin

Associated data

  • ClinicalTrials.gov/NCT03080012